Walleye Capital LLC Makes New $858,000 Investment in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Walleye Capital LLC purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIGet Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,320 shares of the company’s stock, valued at approximately $858,000.

Other institutional investors also recently modified their holdings of the company. Zions Bancorporation N.A. bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at about $28,000. C M Bidwell & Associates Ltd. acquired a new stake in Maravai LifeSciences during the 1st quarter valued at approximately $38,000. SG Americas Securities LLC acquired a new position in shares of Maravai LifeSciences in the 4th quarter worth approximately $112,000. Point72 Hong Kong Ltd bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $163,000. Finally, Bayesian Capital Management LP increased its position in shares of Maravai LifeSciences by 22.1% during the fourth quarter. Bayesian Capital Management LP now owns 5,245 shares of the company’s stock worth $220,000 after buying an additional 949 shares during the period. Institutional investors own 51.02% of the company’s stock.

Maravai LifeSciences Trading Down 0.7 %

NASDAQ:MRVI opened at $23.14 on Tuesday. Maravai LifeSciences Holdings, Inc. has a one year low of $19.83 and a one year high of $50.18. The company has a market cap of $5.91 billion, a PE ratio of 13.77 and a beta of 0.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.75 and a quick ratio of 6.21. The firm has a 50-day moving average of $24.50 and a 200-day moving average of $29.92.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRVI shares. Morgan Stanley dropped their target price on shares of Maravai LifeSciences from $49.00 to $35.00 and set an “overweight” rating on the stock in a report on Monday, August 8th. TheStreet downgraded Maravai LifeSciences from a “c-” rating to a “d+” rating in a report on Tuesday, July 26th. Robert W. Baird reduced their price objective on shares of Maravai LifeSciences from $40.00 to $34.00 in a research report on Friday, August 5th. The Goldman Sachs Group dropped their target price on shares of Maravai LifeSciences from $44.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th. Finally, Credit Suisse Group assumed coverage on shares of Maravai LifeSciences in a report on Wednesday, August 24th. They issued an “outperform” rating and a $34.00 price target for the company.

About Maravai LifeSciences

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Read More

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.